Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

929 questions · 946 findings · 295 reviews · Headline outcomes only

No studies found 150 · 15.9%GRADE not reported 47 · 5%Very low 312 · 33%Low 262 · 27.7%Moderate 138 · 14.6%High 37 · 3.9%

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Endoscopic vs open or mini‐open carpal tunnel release

Overall improvement at more than 3 months Participants' subjective evaluation · carpal tunnel syndrome

Endoscopic showed no clear difference in overall improvement at more than 3 months Participants' subjective… compared with open or mini‐open carpal tunnel release (low certainty).

1 finding from 1 review

Riluzole vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Betamethasone vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Tiotropium vs placebo

Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium leads to lower number of patients with one or more exacerbations compared with placebo (high certainty).

1 finding from 1 review

Tiotropium vs placebo

Hospital admissions due to exacerbations: number of participants · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium showed no clear difference in number of patients with one or more exacerbations requiring… compared with placebo (moderate certainty).

1 finding from 1 review